Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

NCT06079346 is registered in ClinicalTrials.gov with Oncotelic Inc. as lead sponsor.

NCT NCT06079346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06079346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Lead sponsor
Oncotelic Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 1, 2024
Completion date
June 1, 2027
Enrollment
455 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma